Eli Lilly and Company
https://www.lilly.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Finance Watch: Bain Capital Raises $3bn For Fourth Life Sciences Fund
Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies. Also, Candid debuted with $370m in initial funding, Superluminal closed a $120m series A round, PanTera raised €93m ($102.4m) in series A cash and F2G brought in $100m.
Sanofi And ITM Make Radio Waves
Two licensing deals on the same day show that radiopharmaceuticals is still an active area.
J&J’s Tremfya Gains First IBD Indication, Setting The Stage For A Big Pharma Showdown
The IL-23 inhibitor was approved by the US FDA for ulcerative colitis, joining AbbVie’s Skyrizi and Lilly’s Omvoh.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- Hypnion
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice